A phase 3 trial of Novo Nordisk’s ziltivekimab has missed its primary endpoint, denting the prospects of a molecule analysts tipped to generate blockbuster sales and diversify the company’s portfolio.
Hope now rests with the ongoing Artemis and Hermes trials—although analysts have their doubts.
Today's results come from the Zeus study, which compared the effect of once-monthly subcutaneous doses of ziltivekimab, an antibody against the IL‑6 ligand, to placebo in more than 6,300 people. Subjects had atherosclerotic cardiovascular disease, chronic kidney disease (CKD) and inflammation. Novo bet that inhibiting the IL-6 cytokine could reduce cardiovascular inflammation and, in doing so, prevent outcomes such as heart attack and stroke.
However, while Novo generated evidence that ziltivekimab inhibited the IL-6 pathway, the molecule’s effect on the cytokine failed to translate into a significant reduction in major adverse cardiovascular events. The rate of cardiovascular death, non-fatal heart attack or non-fatal stroke was statistically no lower on ziltivekimab than placebo, causing the trial to miss its primary endpoint.
Martin Holst Lange, M.D., Ph.D., Novo’s chief scientific officer, has consistently characterized the Zeus readout as high risk on conference calls with investors this year. Yet analysts were optimistic heading into the data drop.
Success was highly likely and a clinically significant benefit was probable, Guggenheim Securities analysts assessed in a July 13 note to investors. The analysts defined a clinically significant benefit as a hazard ratio (HR) of 0.85, indicating a 15% benefit. The actual HR was 0.99. BMO Capital Markets analysts put Novo’s chances of achieving at least a 15% benefit at 55% in their own note to investors earlier this week.
The failure to live up to those expectations weakens the prospects of an asset that BMO analysts called “an important opportunity for Novo to extend its cardiovascular presence beyond obesity/diabetes, and establish a differentiated position in inflammation-driven cardiovascular disease.”
That opportunity was potentially lucrative, with Guggenheim analysts predicting that Zeus “could unlock a multibillion-dollar opportunity in CKD alone.” BMO analysts concurred, estimating that positive data in a cardiovascular outcome trial could represent a multibillion-dollar opportunity. The analysts put consensus peak sales at about $3 billion.
Novo still has two chances to rescue ziltivekimab. The Danish drugmaker is testing ziltivekimab in people with heart failure in its Hermes trial and evaluating the drug candidate in patients following an acute heart attack in its Artemis study. Both trials are continuing and scheduled to deliver data in the first half of next year.
Speaking on an earnings call in May, Lange said Novo saw “very, very high potential” across the three indications but warned that the program was “high risk until we’ve seen the first readout.” Zeus’ failure leaves Hermes and Artemis looking even riskier than before, with BMO analysts concluding Friday in their latest note to investors that they now “view it as unlikely that either will read out positively.”
Novo could step up its interest in M&A following “another higher-profile pipeline failure,” the analysts said. A large deal in the cardiovascular, metabolic or rare disease space could “reignite investor interest” in Novo, “helping to alleviate some of the hyper focus on the company's GLP-1 business,” the analysts said.
Facts Only
* A phase 3 trial of ziltivekimab missed its primary endpoint.
* The data comes from the Zeus study, comparing once-monthly subcutaneous doses to placebo in over 6,300 people with atherosclerotic cardiovascular disease, chronic kidney disease (CKD), and inflammation.
* Novo tested the hypothesis that inhibiting the IL-6 cytokine would reduce cardiovascular inflammation and prevent outcomes like heart attack and stroke.
* The rate of cardiovascular death, non-fatal heart attack, or non-fatal stroke was statistically no lower on ziltivekimab than placebo.
* Martin Holst Lange characterized the Zeus readout as high risk.
* Guggenheim Securities analysts defined a clinically significant benefit as a hazard ratio (HR) of 0.85 (15% benefit).
* The actual HR observed in the trial was 0.99.
* BMO Capital Markets estimated Novo’s chances of achieving at least a 15% benefit at 55%.
* Novo is testing ziltivekimab in heart failure patients via the Hermes trial and in patients following an acute heart attack via the Artemis study.
* Both the Hermes and Artemis trials are scheduled to deliver data in the first half of next year.
Executive Summary
A Phase 3 trial of Novo Nordisk’s ziltivekimab failed to meet its primary endpoint, which has dampened expectations for the molecule's potential blockbuster sales and portfolio diversification. The results from the Zeus study compared once-monthly subcutaneous doses of ziltivekimab against placebo in over 6,300 subjects with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. While Novo generated evidence that ziltivekimab inhibited the IL-6 pathway, the treatment did not result in a statistically significant reduction in major adverse cardiovascular events; the rate of these events was no lower on ziltivekimab than on placebo.
Despite this outcome, optimism remains centered on ongoing trials, specifically the Artemis trial for heart failure patients and the Hermes trial evaluating the drug candidate in acute heart attack survivors. Analysts have previously expressed optimism regarding potential benefits, estimating a 15% benefit (hazard ratio of 0.85), though the actual observed hazard ratio was 0.99. This outcome weakens prospects for ziltivekimab as an asset in inflammation-driven cardiovascular disease. Novo is exploring mergers and acquisitions to reignite investor interest in its pipeline, seeking a deal in the cardiovascular, metabolic, or rare disease space.
Full Take
The narrative presents a classic tension between biological mechanism demonstration and clinical outcome success, creating a divergence between scientific promise and market valuation. The initial hypothesis—that modulating IL-6 would yield significant cardiovascular benefits—was not validated by the primary endpoint. This failure introduces complexity into assessing the drug’s future value, shifting focus from the direct efficacy signal to its potential in broader disease contexts like CKD and inflammation management.
The subsequent investment response appears driven less by the specific failure of the primary endpoint and more by the perceived remaining optionality within the pipeline. The expectation that ziltivekimab could unlock multi-billion dollar opportunities, particularly in CKD, suggests investors are willing to bet on secondary or extrapolated benefits if those potential avenues materialize. This creates a pattern where the narrative shifts from direct proof of efficacy to speculative positioning around future trials (Hermes and Artemis).
The underlying implication is that value creation in this space relies heavily on establishing differentiated positions based on pathways, rather than achieving single endpoint milestones. The failure has introduced significant uncertainty, yet the persistence of investment interest points toward a market willing to price in potential upside derived from alternative applications or subsequent trial results. What assumptions are being made about the relationship between IL-6 inhibition and complex cardiovascular endpoints, and what is the risk associated with monetizing an asset based on extrapolated potential rather than concrete success?
Sentinel — Human
The text reads like an informed financial news report that synthesizes trial results, analyst commentary, and future pipeline positioning rather than raw data presentation.